Barclays lowered the firm’s price target on Sapiens (SPNS) to $28 from $30 and keeps an Underweight rating on the shares following the Q4 report. The firm says 2025 looks like a transition year for the company as management invests in generating higher growth through optimizing product offering, and leveraging its existing customer base.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPNS:
- Sapiens Reports Growth in Q4 2024 Earnings
- Sapiens International’s Positive Earnings Call Highlights Growth
- Hold Rating on Sapiens International: Navigating Transition with Strategic Investments Amidst Cloud-Based Challenges
- Morning Movers: Medtronic dips following third quarter results
- Sapiens International Corporation Reports 2024 Financial Growth